Formation of peptide impurities in polyester matrices during implant manufacturing

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 49, Issue 3, 2000, Pages 253-257

  Rothen Weinhold, A ^a,b   Oudry, N ^a   Schwach Abdellaoui, K ^a   Frutiger Hughes, S ^a   Hughes, G J ^a   Jeannerat, D ^a   Burger, U ^a   Besseghir, K ^c   Gurny, R ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b F 74166   (France)

^c DEBIOPHARM SA   (Switzerland)

Author keywords

Impurity; Melt processing; Peptide; Polylactic acid; Vapreotide

Indexed keywords

POLYESTER; POLYLACTIC ACID; VAPREOTIDE;

ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPLANT; NUCLEAR MAGNETIC RESONANCE; PROTEIN DEGRADATION;

ANALGESICS; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PEPTIDES; POLYMERS; SOMATOSTATIN;

EID: 0034595305     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00066-7     Document Type: Article

References (13)

1. Pitt C.G. The controlled parenteral delivery of polypeptides and proteins. Int. J. Pharm. 59:1990;173-196.
2. Rothen-Weinhold A., Besseghir K., Gurny R. Analysis of the influence of polymer characteristics and core loading on the in vivo release of a somatostatin analogue. Eur. J. Pharm. Sci. 5:1997;303-313.
3. Rothen-Weinhold A., Besseghir K., Vuaridel E., et al. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur. J. Pharm. Biopharm. 48:1999;113-121.
4. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 6:1989;903-918.
5. Witschi C., Doelker E. Peptide degradation during preparation and in vitro release testing of poly(L-lactic acid) and poly(DL-lactic-co-glycolic acid) microparticles. Int. J. Pharm. 171:1998;1-18.
6. Groves M.J., Teng D. The effect of compaction and moisture on some physical and biological properties of proteins. Ahern T.J., Manning M.C. Stability of Protein Pharmaceuticals. Part A: Chemical and Physical Pathways of Protein Degradation. 1992;311-359 Plenum Press, New York.
7. Lai M.C., Topp E.M., Schowen R., Borchardt R.T. Peptide stability in polymer matrices. Proc. Int. Symp. Control. Rel. Bioact. Mater. 22:1995;532-533.
8. Rothen-Weinhold A., Besseghir K., Vuaridel E., Sublet E., Oudry N., Gurny R. Stability studies of a somatostatin analogue in biodegradable implants. Int. J. Pharm. 178:1998;213-221.
9. Croasmun W.R., Carlson R.M.K. Two-Dimensional NMR-Spectroscopy. Applications for Chemists and Biochemists. 1994;VCH-Publishers, Weinheim.
10. Ermer J., Kibat P.-G. quality concept for impurities during drug developments-use of the hyphenated LC-MS technique. Pharm. Sci. Tech. Today. 1:1998;76-82.
11. Bichsel V.E., Curcio V., Gassmann R., Otto H. Requirements for the quality control of chemically synthesized peptides and biotechnologically produced proteins. Pharm. Acta Helvetiae. 71:1996;439-446.
12. Spassky N. Stereospecific and anionic ring-opening polymerization. Makromol. Chem. Macromol. Symp. 42/43:1991;15-49.
13. Abdellaoui K., Boustta M., Vert M., Morjani H., Manfait M. Metabolic-derived artificial polymers designed for drug targeting, cell penetration and bioresorption. Eur. J. Pharm. Sci. 6:1998;61-73.